This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer

This clinical trial is comparing morning infusions of the study drug (pembrolizumab) to random infusion scheduling for patients with non-small cell lung cancer. Participants will be randomized to either the Intervention (Morning Group) where Infusion start times are restricted between 0800 AM and 1000 AM or to the Control (Standard of Care) group where scheduling will occur as standard of care scheduling, in which infusions are scheduled without respect to a specific time of day. There are past studies that suggest the timing of treatment may influence immune response and outcomes. This idea

Trial Details

NCT ID
NCT06882174
Phase
PHASE2
Sponsor
AHS Cancer Control Alberta
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Scheduling of the time of pembrolizumab infusions
Locations (sample)
  • Edmonton, Alberta, Canada|53.55014,-113.46871

Key Eligibility Criteria

  • Patients with histologic diagnosis mNSCLC with PDL1 staining ≥ 50% on standard of care IHC testing
  • Patients must be eligible for treatment with standard-of-care pembrolizumab
  • Patients must be 18 years of age or older.
  • Patients must be capable of providing consent to enrolment and willing to comply with study, treatment and follow-up.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →